Top Markets
Coin of the day
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
株式のランク #16315
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
株価
$0.94180721
時価総額
$22.26M
変化(1日)
0.38%
変化(1年)
-14.35%
FR
取引 Valbiotis SA (ALVAL)

カテゴリー

Valbiotis SA(ALVAL)の利益
Dec 2025 時点の利益 TTM: $-11.05M
Valbiotis SA の最新の財務報告によると、同社の現在の利益は $-11.05M です。2023 年には $-10.39M の利益を上げ、これは 2022 年の利益 $-15.24M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Valbiotis SA の利益の推移(2015 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-11.05M 6.26%
2024 $-10.40M 0.09%
2023 $-10.39M -31.83%
2022 $-15.24M 28.45%
2021 $-11.86M 91.50%
2020 $-6.19M -17.90%
2019 $-7.54M 32.17%
2018 $-5.71M 94.72%
2017 $-2.93M 369.81%
2016 $-623.95K -40.51%
2015 $-1.05M 0.00%
同業他社の利益
企業 利益 利益の差
$24.72B -223,839.46%
DK
$5.17B -46,859.02%
US
$5.16B -46,779.37%
US
$2.14B -19,450.04%
BE
$1.48B -13,505.47%
NL